3 recruiting, 2 not yet recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Primary Mediastinal B Cell Lymphoma: new trials by email Literature Review of Primary Mediastinal B Cell Lymphoma trials Research Report on Primary Mediastinal B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| Neurocognitive Assessment in Long-Term Survivors of Lymphoma anthracycline containing regimen - Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 100 | 2026-09-01 | 2026-06-22 | |
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context Primary Mediastinal B Cell Lymphoma | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 50 | 2022-04-23 | 2025-01-30 | |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Completed | University Hospital Southampton NHS Foundation Trust | 592 | 2021-03-11 | 2024-02-06 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell, Peripheral (2) · Burkitt Lymphoma (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Cutaneous (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma (4) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (2) · Chronic Disease (1) · DNA Virus Infections (1) · Disease Attributes (1) · Epstein-Barr Virus Infections (1)
Sirolimus (1) · pembrolizumab (1) · ruxolitinib (1)
AbelZeta Inc. (1) · Fondazione Italiana Linfomi - ETS (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Seda S. Tolu (1) · Umoja Biopharma (1) · University Hospital Southampton NHS Foundation Trust (1)
United States (3) · Italy (2) · United Kingdom (1)
Luke Walker, MD (1) · Pier Luigi Zinzani, MD (1) · Seda Tolu, MD (1) · Silvia Franceschetti (1) · Yihong Yao, PhD (1)